|Videos|March 22, 2022
PharmExec CEO Roundtable: Post-COVID Improvements
In this segment, leaders suggest areas to continue building on lessons learned during COVID, including the pharma industry as a tech destination and impact on patient outcomes.
Advertisement
Please read the
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
2
The Evolving Relationship Between FDA and Biotech
3
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
4
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
5